<DOC>
	<DOCNO>NCT00694785</DOCNO>
	<brief_summary>To evaluate effect ARC1779 , therapeutic oligonucleotide ( `` aptamer '' ) patient Type2B von Willebrand Disease .</brief_summary>
	<brief_title>A Study Pharmacokinetics , Pharmacodynamics , Safety ARC1779 Injection Patients With Von Willebrand Disease Type 2B</brief_title>
	<detailed_description>ARC1779 investigate open-label , uncontrolled study 3 vWD-2B patient . Patients vWD-2B screened eligibility base primarily upon single major criterion , i.e. , presence degree chronic thrombocytopenia . Eligible patient treat intravenous infusion ARC1779 72 hour .</detailed_description>
	<mesh_term>Von Willebrand Diseases</mesh_term>
	<mesh_term>Von Willebrand Disease , Type 2</mesh_term>
	<criteria>Male female patient ; ≥ 16 ≤ 75 year age ; Diagnosis VWD2B accord national expert guideline USA [ 1 ] Europe [ 2 ] base medical history finding matrix laboratory assay may include : platelet count , concentration VWF antigen ( VWF : Ag ) , VWF ristocetin cofactor activity ( VWF : RCo ) , Factor VIII ( FVIII ) activity , ristocetininduced platelet aggregation ( RIPA ) , platelet function analyzer ( PFA100® ) closure time , bleed time ( BT ) , VWF multimer test , VWF : plateletbinding ( VWF : PB ) activity , etc . ) Thrombocytopenia ( define platelet count &lt; 100 per nL least 2 occasion within month precede enrollment ; Female patient reproductive age must enrol within 1 7 day cessation precede menses ; Female patient must nonpregnant willing use effective , redundant method contraception ( i.e. , self male partner ) throughout study least 30 day discontinuation study drug treatment ; Male patient must agree use medically acceptable contraceptive ( abstinence use condom spermicide ) throughout study least 30 day discontinuation study drug treatment ; All patient must capable understand comply protocol must sign informed consent document . Patients possible coexist alternative hematologic diagnosis account laboratory finding thrombocytopenia , etc . ; Any significant medical comorbidity would pose increase risk bleeding ( e.g. , recent trauma surgery , history gastrointestinal ulcer , etc . ) thrombosis ( e.g. , history recurrent deep vein thrombosis ( DVT ) .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2009</verification_date>
</DOC>